The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SOFTSWISS, a global provider of innovative iGaming solutions with over 15 years of experience, launches SOFTSWISS Excellence Talks. The YouTube series connects professionals with inspiring leaders ...

As Netflix subscribers are undoubtedly aware, the streamer’s selection of beloved sitcoms has been slashed in recent years. Once home to Friends, The Office, Schitt’s Creek, and more, the ...

The Challenger 300's story began in the late 1990s when Bombardier identified a gap in its product lineup. According to Flight International, at the time, the company offered the larger Challenger 604 ...

Lucerne-based steelmaker Swiss Steel is sticking to its restructuring plans, even with the emergency aid pledged by parliament. The company plans to cut 130 jobs at its Steeltec production site in ...

DALLAS--(BUSINESS WIRE)--Colossal Biosciences, the world’s first de-extinction company, has today announced $200M in a Series C financing by TWG Global, a diversified holding company with ...

Shares of SGS have risen more than a quarter over the last 12 months, giving the company a market value of 17.6 billion Swiss francs ($19.2 billion). Bureau Veritas is up by a similar amount over ...

Gauss adds: “The engine is over-performing on wing. That was the idea behind us investing [in the A220, then the Bombardier CSeries, in 2016]. We want to fly that engine, but we need it to be ...

Campers and RV enthusiasts of all types can be the first to see the latest innovation in RVs in Florida this week. Grand Design RV® announced today the consumer debut of the highly anticipated ...

In the 10th megaround of 2025, Umo­ja Bio­phar­ma has banked $100 mil­lion in a Se­ries C fundraise with an eye to ad­vanc­ing its pipeline of … ...

Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell therapies into the clinic. Umoja’s only clinical-stage candidate is UB ...